Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

Schrödinger; SGR-2921; leukaemia; acute myeloid leukaemia (AML); myelodysplastic syndromes (MDS); CDC7 inhibitor; clinical trial halt; patient deaths; drug safety

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

Response Pharmaceuticals; RDX-002; GLP-1 discontinuation; weight regain; obesity; Phase II clinical trial; postprandial triglycerides; cardiometabolic health; iMTP inhibitor

Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks

Eli Lilly; Texas Attorney General; kickback scheme; drug prescriptions; Mounjaro; Zepbound; GLP-1 drugs; Medicaid fraud; Free Nurse Program; Support Services Program; Ken Paxton; pharmaceutical litigation

AbbVie Invests $195 Million in New North Chicago API Manufacturing Site

AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production